Ad is loading...
SCAVX
Price
$15.52
Change
-$0.14 (-0.89%)
Updated
Nov 15 closing price
VISVX
Price
$49.63
Change
-$0.34 (-0.68%)
Updated
Nov 15 closing price
Ad is loading...

SCAVX vs VISVX

Header iconSCAVX vs VISVX Comparison
Open Charts SCAVX vs VISVXBanner chart's image
AB Small Cap Value A
Price$15.52
Change-$0.14 (-0.89%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index I
Price$49.63
Change-$0.34 (-0.68%)
VolumeN/A
CapitalizationN/A
SCAVX vs VISVX Comparison Chart
Loading...
View a ticker or compare two or three
VS
SCAVX vs. VISVX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCAVX is a Buy and VISVX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX has more cash in the bank: 57.6B vs. SCAVX (621M). VISVX pays higher dividends than SCAVX: VISVX (1.90) vs SCAVX (0.23). SCAVX was incepted earlier than VISVX: SCAVX (10 years) vs VISVX (27 years). SCAVX is a more actively managed with annual turnover of: 59.00 vs. VISVX (16.00). SCAVX has a lower initial minimum investment than VISVX: SCAVX (2500) vs VISVX (3000). VISVX (28.71) and SCAVX (28.18) have marching annual gain over last year. VISVX return over 5 years is better than : 57.32 vs. SCAVX (26.48).
SCAVXVISVXSCAVX / VISVX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence10 years27 years-
Gain YTD13.53315.43388%
Front LoadN/AN/A-
Min. Initial Investment2500300083%
Min. Initial Investment IRAN/AN/A-
Net Assets621M57.6B1%
Annual Yield % from dividends0.231.9012%
Returns for 1 year28.1828.7198%
Returns for 3 years-12.4713.23-94%
Returns for 5 years26.4857.3246%
Returns for 10 yearsN/A108.21-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DX12.420.04
+0.32%
Dynex Capital
PNR105.920.06
+0.06%
Pentair plc
TGNA17.64-0.47
-2.60%
TEGNA
HCTI1.16-0.04
-3.33%
Healthcare Triangle
ATOS1.28-0.09
-6.57%
Atossa Therapeutics